44 related articles for article (PubMed ID: 9678511)
1. Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1.
Nutter CA; Kidd BM; Carter HA; Hamel JI; Mackie PM; Kumbkarni N; Davenport ML; Tuyn DM; Gopinath A; Creigh PD; Sznajder ŁJ; Wang ET; Ranum LPW; Khoshbouei H; Day JW; Sampson JB; Prokop S; Swanson MS
Brain; 2023 Oct; 146(10):4217-4232. PubMed ID: 37143315
[TBL] [Abstract][Full Text] [Related]
2. Sphingolipids in neurodegenerative diseases.
Pan X; Dutta D; Lu S; Bellen HJ
Front Neurosci; 2023; 17():1137893. PubMed ID: 36875645
[TBL] [Abstract][Full Text] [Related]
3. Early defects in mucopolysaccharidosis type IIIC disrupt excitatory synaptic transmission.
Pará C; Bose P; Bruno L; Freemantle E; Taherzadeh M; Pan X; Han C; McPherson PS; Lacaille JC; Bonneil É; Thibault P; O'Leary C; Bigger B; Morales CR; Di Cristo G; Pshezhetsky AV
JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34156977
[TBL] [Abstract][Full Text] [Related]
4. Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression.
Pará C; Bose P; Pshezhetsky AV
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32106459
[TBL] [Abstract][Full Text] [Related]
5. A saposin deficiency model in Drosophila: Lysosomal storage, progressive neurodegeneration and sensory physiological decline.
Hindle SJ; Hebbar S; Schwudke D; Elliott CJH; Sweeney ST
Neurobiol Dis; 2017 Feb; 98():77-87. PubMed ID: 27913291
[TBL] [Abstract][Full Text] [Related]
6. GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin.
Meyer RC; Giddens MM; Schaefer SA; Hall RA
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9529-34. PubMed ID: 23690594
[TBL] [Abstract][Full Text] [Related]
7. Severe vestibular dysfunction and altered vestibular innervation in mice lacking prosaposin.
Akil O; Lustig LR
Neurosci Res; 2012 Apr; 72(4):296-305. PubMed ID: 22326583
[TBL] [Abstract][Full Text] [Related]
8. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
Xu YH; Sun Y; Ran H; Quinn B; Witte D; Grabowski GA
Mol Genet Metab; 2011 Apr; 102(4):436-47. PubMed ID: 21257328
[TBL] [Abstract][Full Text] [Related]
9. Regional expression of prosaposin in the wild-type and saposin D-deficient mouse brain detected by an anti-mouse prosaposin-specific antibody.
Yoneshige A; Suzuki K; Kojima N; Matsuda J
Proc Jpn Acad Ser B Phys Biol Sci; 2009; 85(9):422-34. PubMed ID: 19907127
[TBL] [Abstract][Full Text] [Related]
10. Temporal gene expression profiling reveals CEBPD as a candidate regulator of brain disease in prosaposin deficient mice.
Sun Y; Jia L; Williams MT; Zamzow M; Ran H; Quinn B; Aronow BJ; Vorhees CV; Witte DP; Grabowski GA
BMC Neurosci; 2008 Aug; 9():76. PubMed ID: 18673548
[TBL] [Abstract][Full Text] [Related]
11. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
Moser HW; Moser AB; Hollandsworth K; Brereton NH; Raymond GV
J Mol Neurosci; 2007 Sep; 33(1):105-13. PubMed ID: 17901554
[TBL] [Abstract][Full Text] [Related]
12. Neurolysosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin.
Sikora J; Harzer K; Elleder M
Acta Neuropathol; 2007 Feb; 113(2):163-75. PubMed ID: 17024494
[TBL] [Abstract][Full Text] [Related]
13. Mouse models of human lysosomal diseases.
Suzuki K; Proia RL; Suzuki K
Brain Pathol; 1998 Jan; 8(1):195-215. PubMed ID: 9458176
[TBL] [Abstract][Full Text] [Related]
14. Pathological study of mice with total deficiency of sphingolipid activator proteins (SAP knockout mice).
Oya Y; Nakayasu H; Fujita N; Suzuki K; Suzuki K
Acta Neuropathol; 1998 Jul; 96(1):29-40. PubMed ID: 9678511
[TBL] [Abstract][Full Text] [Related]
15. A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD).
Wrobe D; Henseler M; Huettler S; Pascual Pascual SI; Chabas A; Sandhoff K
J Inherit Metab Dis; 2000 Feb; 23(1):63-76. PubMed ID: 10682309
[TBL] [Abstract][Full Text] [Related]
16. A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice.
Yoneshige A; Suzuki K; Suzuki K; Matsuda J
J Neurosci Res; 2010 Aug; 88(10):2118-34. PubMed ID: 20175216
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids.
Fujita N; Suzuki K; Vanier MT; Popko B; Maeda N; Klein A; Henseler M; Sandhoff K; Nakayasu H; Suzuki K
Hum Mol Genet; 1996 Jun; 5(6):711-25. PubMed ID: 8776585
[TBL] [Abstract][Full Text] [Related]
18. Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell.
Sandhoff K; Kolter T; Van Echten-Deckert G
Ann N Y Acad Sci; 1998 Jun; 845():139-51. PubMed ID: 9668348
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses.
Harzer K; Paton BC; Poulos A; Kustermann-Kuhn B; Roggendorf W; Grisar T; Popp M
Eur J Pediatr; 1989 Oct; 149(1):31-9. PubMed ID: 2514102
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
